Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to Written Parliamentary Question 85637, when his Department expects to publish the research funded by the National Institute of Health and Care Research that will look at how to cost-effectively improve care coordination to align to the needs of patients.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Steps are being taken to improve the coordination of care for all rare diseases as a priority under the UK Rare Diseases Framework. Through the England Rare Diseases Action Plans, which set out actions to deliver against this priority, we commissioned research funded by NIHR to build on the CoOrdinated Care Of Rare Diseases (CONCORD) study with RAND Europe and University of Cambridge. The NIHR-funded CONCORD study sought to investigate how services for people with rare diseases are coordinated in the United Kingdom, and how people living with rare diseases, and healthcare professionals who treat rare diseases, would like them to be coordinated. The new study will help us understand how to best make improvements to care co-ordination in a way which aligns to the needs of patients with rare conditions and which is as cost-effective as possible for the NHS. The study is due to end in May 2026. Findings will be submitted to scientific journals after this date. Further information is avaiable on the CONCORD study at the following link:
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that healthcare professionals are provided with timely guidance on prescribing alternatives when products they routinely prescribe are subject to safety recalls.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Defective Medicines Report Centre (DMRC) is part of the Medicines and Healthcare products Regulatory Agency (MHRA). The role of the DMRC is to minimise the hazard to patients arising from the distribution of defective medicines by providing an emergency assessment and communication system between manufacturers, distributors, wholesalers, pharmacies, regulatory authorities, and users. It achieves this aim by:
Where a medicinal product recall is required, the decision is taken in consultation with the relevant Licence Holder. It is the Licence Holder’s responsibility to ensure that a recall is carried out effectively throughout the distribution chain to the appropriate level. If necessary, the DMRC will issue a Recall Notification to support action taken by the Licence Holder. Where possible, the DMRC will actively engage with the Department to inform us of upcoming recalls, especially where there may be limited marketed products available or critical medicines involved. The Department’s Medicines Supply Team have a range of well-established processes and tools to mitigate risks to patients, and in some circumstances, this can include the prescribing of an alternative medicine.
The Department follows a clear operating framework for managing medicines shortages and, working with National Health Service specialist clinicians, develops appropriate management plans, including comprehensive guidance for prescribers, which are ratified by the Medicines Shortage Response Group to ensure that the most appropriate communication route is used. We work collaboratively with the MHRA throughout the recall process to ensure that when prescribing an alternative medicine should be considered, that this can be communicated in the Recall Notification, or as close to the issue of the Recall Notification that could result in a supply issue.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the size of the anaesthetist workforce in (a) the East of England and (b) St Neots and Mid Cambridgeshire constituency.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has not made a specific assessment of the adequacy of the size of the anaesthetist workforce in the East of England and/or the St Neots and Mid Cambridgeshire constituency. Appropriate National Health Service staffing levels are determined locally.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the number of anaesthetists across the UK.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
We set out in the 10-Year Health Plan for England published in July 2025 that over the next three years we will create 1,000 new specialty training posts with a focus on specialties where there is greatest need.
On 8 December, the Government put an offer in writing to the British Medical Association (BMA) Resident Doctors Committee, which was rejected. The offer would have increased the number of training posts over the next three years from the 1,000 announced in the 10-Year Health Plan to 4,000, bringing forward 1,000 of these training posts to start in 2026. The BMA have rejected the Government's offer, so that is not going ahead. The Government will consider its next steps.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reverse the long-term decline in the amount spent on medicines as a percentage of the NHS budget.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
We continue to support the United Kingdom’s world leading life sciences sector through investment, innovation and reform as set out in our Life Sciences Sector Plan and 10-Year Health Plan, through which we committed to accelerating growth in net spend on innovative medicines to unlock the potential for patients.
As announced as part of our world-leading agreement with the United States, we will increase the amount which the UK pays for life-changing medicines by 25% through changes to the way that medicines are evaluated by the National Institute for Health and Care Excellence (NICE), including an increase to the NICE cost-effectiveness threshold. In this way, we are increasing the value that we place on innovations that deliver improvements to patient health, ensuring faster patient access for vital medicines for cancer, rare diseases and other conditions.
We are giving a clear signal that we want to bring innovative medicines to National Health Service patients, encouraging the life sciences industry to prioritise the UK as an early launch market, and help get the newest available treatments to those who need them.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether integrated care boards will be given additional one-off funding for redundancy programmes to meet the 50% cost reduction target.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Following the Prime Minister’s announcement of the abolition of NHS England, we are clear on the need for a smaller centre, as well as scaling back integrated care board (ICB) running costs and NHS provider corporate cost reductions in order to reduce waste and bureaucracy.
Funding agreements have been agreed with His Majesty’s Treasury to enable redundancies to be funded within the Department for Health and Social Care’s (DHSC’s) Spending Review settlement. In 2025/26 and beyond, DHSC will continue to operate within its funding settlement and will not overspend its budget in order to fund redundancies, nor cut any investment to the frontline. The precise split between financial years and organisations is being worked through as operational delivery planning progresses.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what guidance his Department has given to integrated care boards on covering redundancy programme costs.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Following the Prime Minister’s announcement of the abolition of NHS England, we are clear on the need for a smaller centre, as well as scaling back integrated care board (ICB) running costs and NHS provider corporate cost reductions in order to reduce waste and bureaucracy.
Funding agreements have been agreed with His Majesty’s Treasury to enable redundancies to be funded within the Department for Health and Social Care’s (DHSC’s) Spending Review settlement. In 2025/26 and beyond, DHSC will continue to operate within its funding settlement and will not overspend its budget in order to fund redundancies, nor cut any investment to the frontline. The precise split between financial years and organisations is being worked through as operational delivery planning progresses.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the impact of recent divestments made by the life sciences industry on local economies across England, including St Neots and Mid Cambridgeshire constituency.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
We do not hold specific data on the impact of recent divestments on local economies, including in St Neots and Mid Cambridgeshire, specifically.
We know this has been a challenging time for the life sciences sector, with commercial uncertainty and global competition driving recent divestment decisions. To address this, the Government has agreed a landmark trade deal with the United States which makes the United Kingdom the only country in the world to secure a zero percent tariff on pharmaceutical exports to the US, and preferential terms for medical technology exports. The Government is further securing the confidence of the pharmaceutical industry by committing to invest approximately 25% more in innovative, safe, and effective treatments, which will be the first major increase in over two decades.
We will continue to work with industry to deliver our Life Sciences Sector Plan, improve the commercial environment, and bring the benefits of a growing life sciences sector to local economies across the country.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, to ask the Secretary of State for Health and Social Care, what steps is his Department taking to increase the NICE cost-effectiveness thresholds for new medicines and increase the value that the UK places on medicines.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The pharmaceutical sector and the innovative medicines it produces are critical to our national interest, helping people access life changing treatments, reducing pressure on the health service over the longer-term, and ensuring we have a National Health Service that is fit for the future.
Tens of thousands of NHS patients will benefit from a landmark trade deal between the United Kingdom and the United States, which will secure and expand access to vital drugs, safeguard our medicines supply chain, and drive crucial investment while supporting UK patients and industries. This agreement will increase the amount which the United Kingdom pays for life-changing medicines by 25%, ensuring faster patient access for vital medicines for cancer, rare diseases, and other conditions.
A 25% increase in medicine pricing corresponds to two changes to the way the National Institute for Health and Care Excellence evaluates medicines, specifically a change to the standard cost effectiveness threshold and the introduction of a new value set for judging health states.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the value that NICE-recommended medicines bring to patient outcomes and the UK economy.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) plays a vital role in securing access for National Health Service patients to innovative new medicines in a way that represents value to the taxpayer and supports a thriving United Kingdom life sciences sector. NICE is able to recommend the vast majority of new medicines for use by the NHS at prices that reflect the benefits that they bring to NHS patients and that are fair to all parties. Many thousands of NHS patients have benefitted from access to innovative new medicines as a result of NICE’s important work. The measures that we have announced this year as part of the Life Sciences Sector Plan and Regulation Action Plan will further accelerate patient access to new medicines whilst reducing burdens to industry.